View Cart     Email Updates

Masthead (4k)

[News Index (0.5k)]
[Current News and Info (0.5k)]
[2007 (0.5k)]
[2006 (0.5k)]
[2005 (0.5k)]
[2004 (0.5k)]
[2003 (0.5k)]
[2002 (0.5k)]
[2001 (0.5k)]
[2000 (0.5k)]
[1999 (0.5k)]
[1998 (0.5k)]
[1997 (0.5k)]
[1996 (0.5k)]
[1995 (0.5k)]
[Really Old News (0.5k)]

Contents: News Stories, 2007


December 21, 2007

His-Tagged Protein Detection on Westerns in One Hour: GoldiBlot uses nanotechnology (Ni-NTA-Nanogold) instead of antibodies for rapid, sensitively detection

Nanoprobes, Incorporated is pleased to announce GoldiBlot, a new detection system for His-tagged proteins in immunoblots such as Western blots and dot blots. GoldiBlot is a new type of detection system that provides nanogram-level detection sensitivity within an hour for any protein with a polyhistidine tag. GoldiBlot His-Protein Detection Kit uses Nickel-NTA-gold nanoparticles with autometallographic amplification for rapid, sensitive and specific detection of His-tagged recombinant proteins.

Features and advantages include:

  • Detect His-tagged proteins in an hour.
  • Direct visualization of His-tagged proteins in magenta colored bands. No film, autoradiography or phosphorimager required.
  • More stable than antibodies.
  • Low nanogram-level sensitivity with low background.
  • No antibodies involved.

Nanoprobes, Inc., founded in 1990, researches and develops the applications of gold and other metal nanoparticles to microscopic and biomedical detection, staining and imaging. The company recently introduced AuroVist, a unique gold nanoparticle contrast agent for in vivo animal X-ray imaging. Nanoprobes is a leader in immunogold technology, and offers products including the 1.4 nm Nanogold® immunoprobes and labeling reagents, FluoroNanogold combined fluorescent and gold probes, silver enhancers and gold-based autometallographic enhancers for ultrasensitive detection and visualization of biological targets. New product announcements and information about current products are available on the companys web site (www.nanoprobes.com).

[Western blot developed with GoldiBlot (33k)]

Western blot detection of His-tagged proteins using GoldiBlot His Western Blot kit. Lane M: All Blue protein ladder. Lanes 1-5: His-tagged ATF-1 loaded at 2.5 50 ng (1) 50 ng, (2) 25 ng, (3) 10 ng, (4) 5 ng and (5) 2.5 ng. Lane 6: 100 ng His-tagged YY1. Lane 7: 100 ng His-tagged Src. Lane 8: 50 ng His-tagged Src and bacterial extract with 2,500 ng total E. Coli Protein. Lane 9: bacterial extract with 2,500 ng total E. Coli Protein.

For more information, contact:

Victoria Kowalski
Nanoprobes, Incorporated
95 Horse Block Road
Yaphank, NY 11980-2301
                Telephone: (631) 205-9490
Fax: (631) 205-9493
E-mail: nano@nanoprobes.com
Web: www.nanoprobes.com

contents


August 21, 2007

Review Paper Describes Development and Use of New Enzyme Metallography (EnzMet) Reagent for In Situ Hybridization

Nanoprobes, Incorporated has developed a new system for super-sensitive, high-resolution detection for use in in situ hybridization (ISH) and immunohistochemistry (IHC). The new process uses an enzyme-linked probe to deposit metal from solution at a target site; this provides a dense, punctate, high resolution black stain which is readily distinguished from other commonly used stains. This new detection method, termed "Enzyme Metallography" (EnzMet) has several important advantages for pathology and tissue study. It is visualized in the conventional brightfield light microscope, and hence does not require the use of fluorescent optics or dark adaptation on the part of the user. It provides a permanent record, with no fading or photobleaching; and it can visualize single copies of even non-amplified genes.

The development of this method and its application to HER2 gene amplification in breast cancer are described in a review in the August issue of Human Pathology. Nanoprobes recently signed a deal with Ventana Medical Systems, Incorporated, for commercial development and use of this reagent in their automated slide staining instruments. As a result, the first commercial product has now been introduced in Europe; it is called SISH (Silver In Situ Hybridization). Introduction of SISH in the United States is pending FDA approval. In addition, Nanoprobes will shortly introduce a commercial EnzMetTM formulation optimized for research applications and non-automated staining.

Reference:

  • Powell, R. D.; Pettay, J. D.; Powell, W. C.; Roche, P. C.; Grogan, T. M.; Hainfeld, J. F., and Tubbs, R. R.: Metallographic in situ hybridization. Hum. Pathol., 38, 1145-1159 (2007).

Nanoprobes, Inc., founded in 1990, researches and develops the applications of gold and other metal nanoparticles to microscopic and biomedical staining and imaging. The company recently introduced AuroVistTM, a unique gold nanoparticle contrast agent for in vivo X-ray imaging. Nanoprobes is a leader in immunogold technology, and offers products including the 1.4 nm Nanogold® immunoprobes and labeling reagents, FluoroNanogold combined fluorescent and gold probes, silver enhancers and gold-based autometallographic enhancers for ultrasensitive detection and visualization of biological targets. New product announcements and information about current products are available on the companys web site (www.nanoprobes.com). Nanoprobes recently announced a major expansion to its Yaphank, NY facility.

[Enzyme Metallography: schematic and comparison with DAB (74k)]

Enzyme metallography (EnzMet): (left) how it works. Comparison between conventional DAB detection with H&E counterstain (center) and EnzMet with nuclear fast red counterstain (right) detection of HER2 gene copies in paraffin-embedded infiltrating ductal carcinoma of the breast (micrographs courtesy of Raymond R. Tubbs, Cleveland Clinic Foundation).

For more information, contact:

Victoria Kowalski
Nanoprobes, Incorporated
95 Horse Block Road
Yaphank, NY 11980-2301
                Telephone: (631) 205-9490
Fax: (631) 205-9493
E-mail: nano@nanoprobes.com
Web: www.nanoprobes.com

contents


April 17, 2007

Nanoprobes Introduces "AuroVist" the First Gold Nanoparticle X-Ray Contrast Agent for MicroCT Use

Nanoprobes, Incorporated is proud to announce the commercial release of AuroVist, a new X-ray contrast agent for research animal use based on the companys gold nanoparticle technology. Gold has several advantages over the conventional iodine-based contrast reagents. It is a better contrast element than iodine for both micro-CT and clinical CT applications. At appropriate beam energies, gold achieves a contrast up to 3 times greater than iodine per unit mass, and initial blood contrast greater than 1,000 Hounsfeld Units (HU). Gold concentrations up to four times those of iodine can be achieved, providing a total contrast gain of up to ten times or more. Unlike iodine, AuroVist has very low viscosity and osmolality, and therefore may be injected and used in small blood vessels without risk of vascular damage.

Using AuroVist with this approach, 100 m blood vessels in live animals have already been successfully imaged with microCT, and vascular casts obtained, a goal that has never before been achieved. Small orthotopic colon tumors were also detected in vivo using gold nanoparticles and microCT. Kidney fine structure may be imaged up to an hour or more after injection; concentration in the kidneys can provide contrast values as high as 1,500 HU or more. Acute toxicities were low, and the phamacokinetics of AuroVist have been found to be acceptable even for future human use development.

Nanoprobes, Inc., founded in 1990, researches and develops the applications of gold and other metal nanoparticles to microscopic and biomedical staining and imaging. The company is a leader in immunogold technology and offers a unique range of products, including the 1.4 nm Nanogold® immunoprobes and labeling reagents, FluoroNanogold combined fluorescent and gold probes, and silver enhancers and gold-based autometallographic enhancers for ultrasensitive detection and visualization of biological targets. New product announcements and information about current products are available on the companys web site (www.nanoprobes.com). Nanoprobes recently announced a major expansion to its Yaphank, NY facility.

[AuroVist imaging mouse kidneys (60k)]

MicroCT showing kidneys in live mouse 1 hour after injection with AuroVist (bar = 2 mm).

For more information, contact:

Victoria Kowalski
Nanoprobes, Incorporated
95 Horse Block Road
Yaphank, NY 11980-2301
                Telephone: (631) 205-9490
Fax: (631) 205-9493
E-mail: nano@nanoprobes.com
Web: www.nanoprobes.com

contents


January 10, 2007

Nanoprobes Wins Phase 2 SBIR Grant to Develop Gold Nanoparticle Imaging Agent for MicroCT

Nanoprobes, Incorporated has received a Phase 2 Small Business Innovation Research (SBIR) grant from the National Cancer Institute (National Institutes of Health) to develop gold nanoparticle-based imaging agents for Micro-Computed Tomography (MicroCT). The award of about $850,000 for two years will support the development of gold nanoparticle-based contrast agent products that will then be available to other researchers using microCT that will enable vascular and targeted imaging. A major goal is to make these agents available for microCT and eventual human use. If successful, this effort will produce superior blood pool agents and the first targeted CT contrast agent. The research will be conducted in collaboration with Henry Smilowitz, Ph.D. at the University Of Connecticut Health Center, Avraham Dilmanian, Ph.D. at Brookhaven National Laboratory, and Daniel Slatkin, MD.

Physically, gold is a better contrast element than the conventionally used iodine for both micro-CT and clinical CT. For micro-CT, the beam's energy spectrum can be tailored to be just above golds 12-14-keV L-edge (e.g. 40 kVp), while for clinical CT it can be tuned to be above gold's 80.7-keV K-edge (e.g., 150 kVp with Cu filtration), thus optimizing the image contrast-to-noise ratio for both applications. Using this approach, 20 m blood vessels in live animals have already been successfully imaged with microCT, and vascular casts obtained, a goal that has never before been achieved. Small orthotopic colon tumors were also detected in vivo using gold nanoparticles and microCT. The phamacokinetics and toxicity of the compounds have been found to be acceptable for human use development.

Nanoprobes, Inc., founded in 1990, researches and develops novel microscopic and biomedical staining and imaging technology using metal nanoparticles. The company is a leader in immunogold technology. Other products include the 1.4 nm Nanogold® immunoprobes and labeling reagents, FluoroNanogold combined fluorescent and gold probes, and silver enhancers and gold-based autometallographic enhancers for ultrasensitive detection and visualization of biological targets. New product announcements and information about current products are available on the companys web site (www.nanoprobes.com). Nanoprobes recently announced a major expansion to its Yaphank, NY facility.

For more information, contact:

Victoria Kowalski
Nanoprobes, Incorporated
95 Horse Block Road
Yaphank, NY 11980-2301
                Telephone: (631) 205-9490
Fax: (631) 205-9493
E-mail: nano@nanoprobes.com
Web: www.nanoprobes.com

contents


 

View Cart     Nanoprobes.com
© 1990-2015 Nanoprobes, Inc. All rights reserved. Sitemap